8-K ·Filed Feb 25, 2026

ALKS

Alkermes plc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7mo ago SEC0001193125-26-068927
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Monitor leadership transition execution and Jackson's strategic direction, particularly regarding the integration of Avadel and development of the orexin agonist pipeline. No immediate financial impact expected, but long-term execution risk during transition should be assessed.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d ⚠ clustered
ALKS ▲ +19.19% at T+60d
NEUTRAL call ✓ call won +19.19% · α vs SPY +12.24% · entry $31.03 → $36.98
Entry anchored
Feb 24, 03:59 PM ET
via exchange tick
T+1d
-0.90%
call -0.90% · α -0.36%
$30.75
settled 7mo ago
T+5d
-6.03%
call -6.03% · α -4.93%
$29.16
settled 7mo ago
T+20d
-5.41%
call -5.41% · α -0.18%
$29.35
settled 6mo ago
T+60d
+19.19%
call +19.19% · α +12.24%
$36.98
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

Alkermes plc announced the retirement of CEO and Chairman Richard F. Pops, effective July 31, 2026, after 35 years of service. He will be succeeded by current COO Blair C. Jackson, effective August 1, 2026. Pops will remain as non-executive Chairman and Senior Advisor through December 31, 2026, receiving a $75,000 monthly retainer, pro-rated bonus, and a $2.69 million equity award. The transition reflects a planned succession.

Key Facts

  • Richard F. Pops retires as CEO effective July 31, 2026, after 35 years; remains non-executive Chairman and Senior Advisor through December 31, 2026
  • Blair C. Jackson, current COO, appointed CEO effective August 1, 2026
  • Pops to receive $75,000 monthly retainer as Senior Advisor, pro-rated 2026 bonus, and $2,687,500 restricted stock unit award
  • Pops' equity awards will continue vesting during advisory period, with post-service vesting provisions for up to 21 months
  • Company highlighted strong commercial business, $1.5 billion in annual revenues, and late-stage pipeline including alixorexton for narcolepsy
  • Recent acquisition of Avadel Pharmaceuticals enhances sleep medicine commercial capabilities

Financial Impact

Approximately $2.69 million in equity compensation and $450,000 in cash ($75,000/month for 6 months) for Pops' advisory role, plus pro-rated bonus and board retainer

compensation expenseshare countnon-executive director fees

Risk Factors

  • Execution risk during CEO transition despite planned succession
  • Potential for strategic shift under new leadership affecting R&D priorities
  • Market perception of founder departure despite smooth transition plans

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-068927
Document: alks-ex99_1.htm0001193125-26-068927
Document: 0001193125-26-068927-index-headers.html0001193125-26-068927
Document: 0001193125-26-068927-index.html0001193125-26-068927
Document: 0001193125-26-068927.txt0001193125-26-068927
18 reports for ALKS
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +25.88%May 12, 2026
Filters
Rows
Reports for ALKS — sortable, filterable
TypeNow
Sep 16, 2026
16d ago
8-K
NEUTRAL ★ 2/10
$46.07 $42.13▼ −8.55%▼ −11.12%$41.75 (−9.38%)
Sep 3, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$46.10 $45.83▼ −0.59%▲ +0.62%$41.75 (−9.44%)
Aug 3, 2026
8w ago
Insider Cluster
BEARISH ★ 4/10
$49.67 $49.21▲ +0.93%▲ +0.83%$41.75 (+15.95%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$49.67 $49.21▼ −0.93%▼ −0.83%$41.75 (−15.95%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$49.67 $49.21▼ −0.93%▼ −0.83%$41.75 (−15.95%)
Jul 28, 2026
9w ago
8-K
BEARISH ★ 6/10
$50.50 $49.53▲ +1.92%▲ +4.19%$41.75 (+17.33%)
Jul 8, 2026
12w ago
8-K
NEUTRAL ★ 3/10
$54.29 $51.60▼ −4.95%▼ −5.82%$41.75 (−23.10%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$55.14 $51.94▼ −5.80%▼ −6.29%$41.75 (−24.28%)
Jun 4, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$42.80 $44.28▲ +3.46%▲ +2.89%$41.75 (−2.45%)
Jun 1, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$41.19 $44.29▲ +7.53%▲ +10.50%$41.75 (+1.37%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (65h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access